CDK4 and neoplasm: Additionally, the administration of CDK4/6 inhibitor Palbociclib has been shown to promote CD8+ T cell differentiation into memory-like phenotypes, thereby bolstering the anti-tumor effects of adoptive T cell therapy [16].